Navigation Links
The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Date:3/13/2008

Future Generation Treatment from Abbott Shows No Thrombosis, Low MACE Rates

Out to One Year in Preliminary Clinical Study of Thirty Patients

ABBOTT PARK, Ill., March 13 /PRNewswire-FirstCall/ -- Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (retreatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year. These one year results for Abbott's bioabsorbable everolimus eluting stent were consistent with performance demonstrated by the system at 6 months, as previously reported in October 2007 (http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0529.htm ). Abbott's prospective, non-randomized, ABSORB clinical trial is designed to evaluate the overall safety and performance of a fully bioabsorbable everolimus eluting stent out to 5 years.

"Abbott's bioabsorbable everolimus eluting stent has demonstrated excellent clinical safety out to one year in patients with coronary artery disease," said Patrick W. Serruys, M.D., Ph.D., Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and co-principal investigator in the ABSORB study. "The positive results from this clinical trial form a strong basis for the development of additional bioabsorbable stent platforms with the potential to eliminate some of the restrictions posed by metallic stents in areas such as vessel imaging and vessel remodeling."

At 6 months, the overall MACE rate in the ABSORB trial was 3.3 percent (one patient, n=30) and late loss, a measure of reduction in vessel lumen diameter after stenting, was 0.44 mm. At one year, the o
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
2. The Lancet Publishes Vasogens ACCLAIM Results
3. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
4. Consortium publishes Phase II map of human genetic variation
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
7. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. NPS Pharmaceuticals Reports 2007 Financial Results
10. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... The 2012 federal budget recommends the allocation of ... federal interagency research and development program that studies the ... nanoscale—a measurement of particles between 1 and 100 nanometers ... materials are found in nature as part of smoke, ...
... Metabolex, Inc., a biopharmaceutical company focused on the ... treatment of metabolic diseases, announced today that it has ... its product candidate for the management of hyperuricemia in ... study will evaluate the safety and urate-lowering activity of ...
... Ontario Institute for Cancer Research (OICR) today announced ... bringing promising anticancer technologies to market. ... bring commercial and operational leadership that will accelerate ... assets," said Frank Stonebanks, Vice-President, Commercialization and Chief ...
Cached Biology Technology:Environmental Training Center Prepares Companies to Handle Nanotechnology Environmental and Human Safety Impacts 2Metabolex Initiates Phase 2 Trial of Arhalofenate 2Ontario Institute for Cancer Research Announces Spin Off Companies Developing Promising Anticancer Technologies 2Ontario Institute for Cancer Research Announces Spin Off Companies Developing Promising Anticancer Technologies 3
(Date:4/17/2014)... anthrax detection cartridge developed at Sandia National Laboratories and ... easier, faster and cheaper. , Bacillus anthracis ... in soils all over the world and can cause ... animals. The bacteria can survive in harsh conditions for ... may occur through skin contact, inhalation of spores or ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... parasites and pathogens that devastate honeybees in Europe, Asia ... but do not appear to be impacting native honeybee ... of researchers., The invasive pests include including Nosema ... African honeybees appear to be resilient to these invasive ... to control pests in Europe, Asia and the United ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... New Mexico, July 20, 2011Researchers at the U.S. Department ... Bioenergy Research Center have found a potential key for ... as corn leaves and stalks, or switch grass. ... the American Chemical Society , Los Alamos researchers S. ...
... another major step in sleuthing the 2010 Deepwater Horizon oil ... Institution (WHOI) determined what chemicals were contained in a deep, ... long. The scientists mapped and sampled it last summer ... the Deepwater Horizon oil spill. The researchers took a ...
... The Bureau of Reclamation and Fluid Imaging Technologies ... to improve the capacity and speed of Fluid Imaging ... zebra mussel larvae in water samples. The spread ... potential to impair or interrupt water delivery and hydropower ...
Cached Biology News:Researchers find potential key for unlocking biomass energy 2Chemical make-up of Gulf of Mexico plume determined 2Chemical make-up of Gulf of Mexico plume determined 3Chemical make-up of Gulf of Mexico plume determined 4Reclamation signs research agreement to improve quagga and zebra mussel larvae detection 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Staccato Mini-Workstations provide fast and ... genomics, proteomics and drug development laboratories. ... of instrumentation to automate basic liquid ... Mini-Workstations are controlled with either Caliper's ...
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
... submicron range are part of your production ... of particle size is important to you. ... detect the component populations in your sample ... Analyzer uses Photon Correlation Spectroscopy (PCS) , ...
Biology Products: